- Home
- JELD vs KURA Comparison
JELD vs KURA Comparison
Compare JELD & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JELD
- KURA
- Stock Information
- Founded
- JELD 1960
- KURA 2014
- Country
- JELD United States
- KURA United States
- Employees
- JELD 17700
- KURA N/A
- Industry
- JELD Forest Products
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JELD Basic Materials
- KURA Health Care
- Exchange
- JELD Nasdaq
- KURA Nasdaq
- Market Cap
- JELD 707.4M
- KURA 793.2M
- IPO Year
- JELD 2017
- KURA N/A
- Fundamental
- Price
- JELD $8.36
- KURA $8.86
- Analyst Decision
- JELD Hold
- KURA Strong Buy
- Analyst Count
- JELD 9
- KURA 10
- Target Price
- JELD $13.63
- KURA $30.13
- AVG Volume (30 Days)
- JELD 609.2K
- KURA 2.1M
- Earning Date
- JELD 02-18-2025
- KURA 11-07-2024
- Dividend Yield
- JELD N/A
- KURA N/A
- EPS Growth
- JELD N/A
- KURA N/A
- EPS
- JELD N/A
- KURA N/A
- Revenue
- JELD $3,900,923,000.00
- KURA N/A
- Revenue This Year
- JELD N/A
- KURA N/A
- Revenue Next Year
- JELD N/A
- KURA $106.66
- P/E Ratio
- JELD N/A
- KURA N/A
- Revenue Growth
- JELD N/A
- KURA N/A
- 52 Week Low
- JELD $8.15
- KURA $8.75
- 52 Week High
- JELD $21.75
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- JELD 21.98
- KURA 21.32
- Support Level
- JELD $8.30
- KURA $8.85
- Resistance Level
- JELD $10.79
- KURA $10.02
- Average True Range (ATR)
- JELD 0.40
- KURA 0.46
- MACD
- JELD -0.16
- KURA 0.10
- Stochastic Oscillator
- JELD 7.45
- KURA 4.66
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.